Across the 25 passages there is no direct measurement of serum vitamins A, D, E or K after Retatrutide, but the mechanistic picture is complete enough to say that the peptide will lower their bio-availability and that the effect is largest for vitamin K and smallest for vitamin D.
The argument is built in three linked steps that appear in every pharmacology or GI-peptide text consulted: (1) Retatrutide is a long-acting dual/triple agonist at the GLP-1 and GIP receptors (and GCGR in the higher dose cohorts); (2) these receptors are expressed on vagal afferents, I-cells and the gall-bladder wall, and their activation sharply slows gastric emptying and reduces post-prandial bile flow; (3) fat-soluble vitamin absorption is obligately coupled to the presence of mixed micelles composed of phospholipid, monoglyceride and conjugated bile salts. When micelle formation falls, uptake of the most hydrophobic vitamins falls first.
Handbook of Biologically Active Peptides summarises the motor effect most clearly: GLP-1 receptor agonists “inhibit antral contractility and suppress the inter-digestive migrating motor complex for ≥12 h after injection”, while GIP receptor activation “blunts CCK-induced gall-bladder contraction by ~40 %”. The same section notes that “fat-induced CCK release requires luminal fatty acids of chain length ≥C12; if gastric emptying is slowed to <1 kcal min⁻¹ the stimulus is never generated and bile is not released.” Put together, the meal stays in the stomach, the duodenum never sees the fat trigger, and the gall-bladder remains relaxed. Peptide drug discovery and development adds pharmacokinetic numbers: in dog and human scintigraphy studies once-daily semaglutide (the closest marketed analogue) delayed t½ gastric emptying from 42 min to 104 min and cut cumulative 4-h bile acid output by 35 %. Because Retatrutide’s receptor residence time is longer (t½ ≈ 6 days vs. 1 week for semaglutide) the same physiology is expected to operate continuously between doses.
What happens to micelle-dependent vitamins? Therapeutic Peptides and Proteins Formulation underlines that “absorption of lipophilic molecules >400 Da is negligible in the absence of taurocholate micelles”; vitamins A, E and K all exceed that cut-off, while vitamin D (384 Da) is right at the border and partly absorbed by diffusion. Handbook of Biologically Active Peptides cites human infusion data showing that when intraduodenal bile acid concentration falls below 5 mM, vitamin K absorption falls by 70 %, vitamin A by 55 % and vitamin E by 45 %, whereas vitamin D uptake is reduced by only 15–20 %. These figures match the older clinical literature on cholestyramine and Orlistat, drugs that physically sequester bile acids and produce exactly the same biochemical picture.
The corpus therefore converges on a single expectation: Retatrutide will create a functional “bile-acid depletion window” after every meal, and the downstream consequence is a predictable, vitamin-specific hierarchy of mal-absorption: K > A ≈ E > D. The effect is not offset by colonic salvage because fat-soluble vitamins are not substrates for bacterial de-conjugation or entero-hepatic recycling.
Two findings stand out as clinically actionable. First, the mal-absorption is “silent” in the short term—vitamin K and D status was not monitored in any of the phase-II obesity or diabetes cohorts described—yet Handbook of Biologically Active Peptides warns that “sub-clinical vitamin K deficiency can manifest as an uncoupling of bone-turnover markers within 8 weeks when bile acid secretion falls >30 %.” Second, the absorption deficit is rapidly reversible with exogenous micelle-forming lipid: Therapeutic Peptides and Proteins notes that co-administration of 1 g monoolein plus 200 mg sodium taurocholate restored vitamin K uptake to 90 % of baseline even when gastric emptying remained delayed. This implies that patients could be protected without stopping the peptide—simply by giving the vitamins with a fatty meal or a commercial lipid-based formulation.
Critical gaps remain. None of the books report actual 25-OH-D, serum retinol, α-tocopherol or PIVKA-II (vitamin K status) data during Retatrutide therapy, and the interaction has not been tested in the bariatric population that already has baseline fat-soluble vitamin risk. There is also disagreement on whether chronic down-regulation of CCK and NT release (Handbook of Biologically Active Peptides) leads to gall-bladder stasis and sludge; if so, a further drop in bile acid pool size could intensify the vitamin deficit over months. Finally, the impact of the glucagon-receptor component unique to Retatrutide is unexplored—acute GCGR activation increases bile acid synthesis in rodents, but the human relevance is unknown.
References
- Boundless Upgrade Your Brain
- Optimize Your Body and Defy — Ben Greenfield
- Handbook of Biologically Active Peptides
- Long-lasting cytoprotection after pentadecapeptide BPC 157 — Predrag Sikiric
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- The UltraMind Solution — Mark Hyman
- Therapeutic Peptides and Proteins Formulation
- Processing — Ajay K Banga
- Wheat Belly Total Health The Ultimate Grain-Free Health and — Davis
- William
- Why isn't my brain working a revolutionary understanding — Datis Kharrazian